Portal de Periódicos da CAPES

New Anti-Cu-TETA and Anti-Y-DOTA Monoclonal Antibodies for Potential Use in the Pre-Targeted Delivery of Radiopharmaceuticals to Tumor

1998; Mary Ann Liebert, Inc.; Volume: 17; Issue: 2 Linguagem: Inglês

10.1089/hyb.1998.17.125

2168-7897

Xueqiong Feng, Roger H. Pak, Linda A. Kroger, Justin Moran, David G. DeNardo, Claude F. Meares, Gerald L. DeNardo, Sally J. DeNardo,

Protein purification and stability

Monoclonal antibodies were raised against yttrium(III)-l, 4, 7, 10-tetraazacyclododecane-N,N′,N″,N‴— tetraacetic acid (Y-DOTA) and copper(II)-l, 4, 8, 11-tetraazacyclotetradecane-N,N′,N″,N‴-tetraacetic acid (Cu-TETA). Four hybridomas with high Y-DOTA binding activity and one hybridoma with Cu-TETA activity were selected. MAbs were purified from mouse ascites by Protein A affinity chromatography and characterized. Affinity constants were determined by equilibrium dialysis and the highest affinity Y-DOTA MAb (Kaff = 1.9 × 108 M-1) was further characterized by competitive ELISA. Gd-DOTA competed as well as Y-DOTA, whereas In-DOTA required 740× higher concentrations for 50% inhibition of this Y-DOTA MAb binding to human serum albumin-Y-DOTA-coated microtiter plates. These anti-metal chelate MAbs have potential use as vehicles for the pretargeted delivery of radiometal chelates to tumors.